Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Genomic analysis of Japanese gastric cancer (345 gastric cancers of NCC)

ABSTRACT: As a contribution to the International Cancer Genome Consortium, whole exome sequencing of 345 Japanese gastric cancer (345 gastric cancers of NCC) with various histological subtypes have been conducted. This study aims to identify unique and common driver genes and molecular subtypes in Japanese gastric cancer.

PROVIDER: EGAS00001002884 | EGA |

REPOSITORIES: EGA

ACCESS DATA

Json Xml

Similar Datasets

WGS of gastric cancer in the Japanese population (81 gastric cancers of NCC)

Project description:As a contribution to The International Cancer Genome Consortium Accelerating Research in Genomic Oncology (ICGC ARGO), whole-genome sequencing of 81 cases from Japanese gastric cancer with various histological subtypes has been conducted. This study aims to reveal the landscape of structural variants (SV) in gastric cancer and analyze mutational and rearrangement signatures simultaneously

| EGAS00001006051 | EGA

Exome sequencing of 142 gastric cancer and matched normal from Japanese cohorts (UT)

Project description:As a contribution to the International Cancer Genome Consortium, exome sequencing of 142 Japanese gastric cancer with various histological subtypes have been conducted. This study aims to identify unique and common driver genes and molecular subtypes in Japanese gastric cancer. Please refer ICGC website for detail: http://icgc.org/icgc/cgp/69/420/1012357

| EGAS00001002891 | EGA

Exome sequencing of 102 gastric cancer and matched normal from Japanese cohorts (YCU)

Project description:As a contribution to the International Cancer Genome Consortium, exome sequencing of 102 Japanese gastric cancer with various histological subtypes have been conducted. This study aims to identify unique and common driver genes and molecular subtypes in Japanese gastric cancer. Please refer ICGC website for detail: http://icgc.org/icgc/cgp/69/420/1012357

| EGAS00001002892 | EGA

DATASET_GC_WES - samples

Project description:fastq of 345 Japanese gastric cancer

| EGAD00001004051 | EGA

Gene expression profiling of human gastric tumors and adjacent non-cancerous mucosa

Project description:Gastric cancer is a heterogeneous disease. The molecular mechanism behind the development of gastric cancer and the different histological subtypes, are yet not completely clear. A better understanding of this may result in better prevention, early diagnosis and treatment strategies. In this study we analyzed gene expression in tumor, adjacent non-cancerous mucosa biopsies and in age/sex matched samples from healthy individuals.

2014-09-03 | E-MTAB-1338 | biostudies-arrayexpress

ena-DATASET-RCAST-15-03-2018-10:53:32:709-233 - samples

| EGAD00001004041 | EGA

ena-DATASET-RCAST-15-03-2018-10:58:42:462-235 - samples

| EGAD00001004042 | EGA

Long Noncoding RNA uc.345 promotes tumorigenesis of pancreatic cancer by upregulation of hnRNPL expression

Project description:Increasing evidence points to an important functional or regulatory role of long noncoding RNA in cellular processes as well as some cancer diseases result from the aberrant lncRNA expression. LncRNA could participate in the cancer progross and develop a significant role through the interaction with proteins. In the present study, we report a lncRNA termed uc.345 that is up-regulated in tumor tissues, compared to the corresponding noncancerous tissues. We found that a higher uc.345 expression lever was significantly more frequent in tissues with increased depth of invasion and advanced TNM tumor node metastasis T stage. Moreover, uc.345 serves as an independent risk factor for pancreatic cancer patients’ overall survival (OS). Through soft agar assay and tumor xenograft model, our results indicate that uc.345 could stimulate tumor growth in vitro and in vivo. We also found the uc.345 could upregulate the hnRNPL protein level, furthermore, we demonstrate that the inhibition of (hnRNPL) by its association with uc.345 contributes to depress tumorgenesis in vitro. Collectively, these results demonstrate that uc.345 functions as an oncogenic lncRNA that promotes tumor progression and serves as a poor predictor for pancreatic cancer patients' overall survival.

2016-09-06 | GSE86436 | GEO

Molecular subtypes in gastric cancer.

Project description:Molecular subtypes in gastric cancer.

| PRJNA329144 | ENA

Proteomic signatures of diffuse and intestinal subtypes of gastric cancer

Project description:Gastric cancer is a leading cause of death from cancer globally. Gastric cancer is classified into intestinal, diffuse and indeterminate subtypes based on histology according to the Laurén classification. The intestinal and diffuse subtypes, although different in histology, demographics and outcomes, are still treated in the same fashion. This study was designed to discover proteomic signatures of diffuse and intestinal subtypes. Mass spectrometry-based proteomics using tandem mass tags (TMT)-based multiplexed analysis was used to identify proteins in tumor tissues from patients with diffuse or intestinal gastric cancer with adjacent normal tissue control. A total of 7,804 or 5,166 proteins were identified from intestinal or diffuse subtype, respectively. This quantitative mass spectrometric analysis defined a proteomic signature of differential expression across the two subtypes, which included gremlin1 (GREM1), bcl-2-associated athanogene 2 (BAG2), olfactomedin 4 (OLFM4), thyroid hormone receptor interacting protein 6 (TRIP6) and melanoma-associated antigen 9 (MAGE-A9) proteins. Although GREM1, BAG2, OLFM4, TRIP6 and MAGE-A9 have all been previously implicated in tumor progression and metastasis, they have not been linked to intestinal or diffuse subtypes of gastric cancer. Using immunohistochemical labelling of a tissue microarray comprising of 132 cases of gastric cancer, we validated the proteomic signature obtained by mass spectrometry in the discovery cohort. Our findings should help investigate the pathogenesis of these gastric cancer subtypes and potentially lead to strategies for early diagnosis and treatment.

2022-02-17 | PXD026279 | Pride

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data